Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant

Journal of Investigative Dermatology

Volumn 108, Issue 6, 1997, Pages 933-937

  Randazzo, Bruce P ^a,b   Bhat, Mulki G ^b   Kesari, Santosh ^a,b   Fraser, Nigel W ^a   Brown, S Moira ^c  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Experimental neoplasm; HSV 1; ICP 34.5

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL STRAIN BHK; CONTROLLED STUDY; CYTOLYSIS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MELANOMA; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SUBCUTANEOUS TISSUE TUMOR; TUMOR CELL LINE; TUMOR REGRESSION; VIRUS ATTENUATION; VIRUS MUTANT; VIRUS REPLICATION;

EID: 0030914772     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/1523-1747.ep12295238     Document Type: Article

References (34)

1. Anonymous: Deaths from melanoma United States, 1973-1992. MMWR 44:343-347, 1995
2. Balch CM, Soong S-j, Murad T M. Smith JW. Maddox WA, Durant JR: A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1:126-132, 1983
3. Bolovav CA, Sawtell NM, Thompson RI.: ICP 34.5 mutants of herpes simplex virus type 1 strain 17syn + are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures. J Virol 68:48-55, 1994
4. Bonnekoh B, Greenhalgh DA, Bundman DS, Eckhardt JN, Longley MA, Chen SH, Woo SL, Roop DR: Inhibition of melanoma growth by adenoviral-mediated HSV thymidine kinase gene transfer in viro. J Invest Dermatol 104:313-317, 1995
5. Boviatsis FJ, Chase M, Wei MX, Tamiya TRK, Hurford J, Kowall NW, Tepper R I, Breakfield XO, Chiocca EA: Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus (HSV), and retrovirus vectors. Hum Gene Therapy 5:183-191, 1994
6. Chou J, Kern ER, Whitley RJ, Roizman B.: Mapping of herpes simplex virus neurovirulence to gamma 1 34.5, a gene nonessential for growth in culture. Science 250:1262-1266, 1990
7. Dupressoir T, Vanacker J-M, Cornells JJ, Duponchel N, Rommelacre J: Inhibition by parvovirus H-1 of the formation of tumors in nude inice and colonies in vitro by transformed human mammary epithelial cells. Cancer Res 49:3203-3208, 1989
8. Gesser RM, Valyi-Nagy T, Fraser NW: Restricted herpes simplex virus type 1 gene expression within sensory neurons in the absence of functional B and T lymphocytes. Virol 200:791-795 , 1994
9. Golumbek PT, Hamzeh FM, Jagffe EM, Levitsky H, Lietman PS, Pardoll DM: Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. J Immunother 12:224-230, 1992
10. Jia WW-G, McDermott M, Goldie J, Cynader M, Tan J, Tufaro, F: Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1. J Natl Cancer Inst 86:1209-1215, 1994
11. Johnson TM, Smith JW, Nelson BR, Chang A.: Current therapies for cutaneous melanoma. J Am Acad Dermatol 32:689-707, 1995
12. Juhasz I, Albelda S, Elder D, Murphy G, Adachi K, Herlyn D, Valyi-Nagy I, Herlyn M: Growth and invasinn of human melanomas in human skin grafted to immunodeficienr mice. Am J pathol 143:528-537, 1993
13. Kesari S,Randazzo BP, Valyi-Nagy T, Huang QS, Brown SM, MacLean AR, Lee VM-Y, Trojanowski JQ, Fraser NW: Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Invest 73:636-648, 1995
14. Klein G, Boon T: Tumor immunology: present perspectives. Curr Opin Immunol 5:719-725, 1993
15. Kucharczuk JC, Randazzo BP, Chang MY, Amin KM, Elshami AA, Sterman DH, Rizk NP, Molnar-Kimber KL, Brown SM, MacLean AR, Litzky LA, Fraser NW, Albelda SM, Kaiser LR: Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Res, 57:466-471, 1997
16. MacLean AR, Ul-Fareed M, Robertson L, Harland J, Brown SM: Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J Gen Virol 72:631-639, 1991
17. Markert JM, Coen DM, Malick A, Mineta T, Martuza RL: Expanded spectrum of viral therapy in the treatment of nervous system tumors. J Neurosurg 77:590-594, 1992
18. Markert JM, Malick A, Coen DM, Martuza RL: Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 32:597-603, 1993
19. Martuza RL, Malick A, Markert JM, Ruffner KI, Coen DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252:854-856, 1991
20. Mckie EA, MacLean AR, Lewis AD, Cruickshank G, Rampling R, Barnett SC, Kennedy PGE, Brown SM: Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumors - evaluation of a potentially effective clinical therapy. Br J Cancer 74:745-752, 1996
21. Mineta T, Rabkin SD, Martuza RL: Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 54:3963-3966, 1994
22. Notarianni EL, Preston CM: Activation of cellular stress protein genes by herpes simplex virus temperature-sensitive mutants which overproduce immediate early polypeptides. Virology 123:113-122, 1982
23. Ram Z, Culver KW, Wallbridge S, Blaese RM, Oldfield EH: In situ retroviralmediated gene transfer for the treatment of brain tumors in rats. Cancer Res 53:83-88, 1993
24. Randazzo BP, Kesari S, Gesser RM, Alsop D, Ford JC, Brown SM, MacLean AR, Fraser NW: Treatment of experimental intracranial murine melanoma with a neuro-attenuated Herpes Simpex virus-1 mutant. Virology 211:94-101, 1995
25. Randazzo BP, Kucharczuk JC, Litzky L, Kaiser L, Brown S, Maclean A, Albelda S, Fraser N: Herpes simplex 1716 - an ICP 34.5 mutant - is severely replication restricted in human skin xenografts in vivo. Virology 223:392-396, 1996
26. Reichard KW, Lorence RM, Cascino CJ, Peeples ME, Walter RJ, Fernando MB, Reyes HM, Greager JA: Newcastle disease virus selectively kills human tumor cells. J Surg Res 52:448-453, 1992
27. Robertson LM, MacLean AR, Brown SM: Peripheral replication and latency reactivation kinetics of the non-neurovirulent herpes simplex virus type-1 variant 1716. J Gen Virol 73:967-970, 1992
28. Spivack JG, Fareed MU, Valyi-Nagy T, Nash TC, O'Keefe JS, Gesser RM, McKie EA, MacLean AR, Fraser NW, Brown SM: Replication, establishment of latent infection, expression of the latency-associated transcripts and explant reactivation of herpes simplex virus type 1 gamma 34.5 mutants in a mouse eye model. J Gen Virol 76:321-332, 1995
29. Spivack JG, Fraser NW: Detection of herpes simplex type 1 transcripts during latent infection in mice. J Virol 61:3841-3847, 1987
30. Taha MY, Brown SM, Clements GB, Graham DI: The JH2604 deletion variant of herpes simplex virus type 2 (HG52) fails to produce necrotizing encephalitis following intracranial inoculation of mice. J Gen Virol 71:1597-1601, 1990
31. Takamiya Y, Short MP, Moolten FL, Fleet C, Mineta R, Breakenfield XO, Martuza RL: An experimental model of retrovirus gene therapy for malignant brain tumors. J Neurosurg 79:104-110, 1993
32. Valyi-Nagy T, Fareed MU, O'Keefe JS, Gesser RM, MacLean AR, Brown SM, Spivack JG, Fraser NW: The HSV-1 strain 17+ gamma 34.5 deletion mutant 1716 is avirulent in SCID mice. J Gen Virol 75:2059-2063, 1994
33. Vile RG, Hart IR: Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 53:3860-3864, 1993
34. Whitley RJ, Kern ER, Chatterjee S, ChoiJ, Roizman B: Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. J Clin Invest 91:2837-2843, 1993